Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRADFORD A BRABEC

Allopathic & Osteopathic Physicians Pediatrics

NPI
1700863826
CMS profile
213505
Location
LINCOLN, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$25.70

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $25.70 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $25.70 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRADFORD A BRABEC

NPI 1700863826 · CMS profile ID 213505

Allopathic & Osteopathic Physicians / Pediatrics

LINCOLN, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700863826?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRADFORD A BRABEC, NPI 1700863826, CMS profile ID 213505. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700863826?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BRADFORD A BRABEC, NPI 1700863826, CMS profile ID 213505. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700863826?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BRADFORD A BRABEC, NPI 1700863826, CMS profile ID 213505, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1700863826?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $25.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $25.7004/12/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1238005972 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,944.37 16
PY2020 $26.17 2
PY2021 $78.22 6
PY2022 $28.87 2
PY2023 $357.26 8
PY2024 $992.59 2
PY2025 $25.70 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $186,978.56 17
PY2024 Principal investigator $95,383.48 11
PY2023 Recipient $28,195.18 4
PY2023 Principal investigator $164,446.72 32
PY2022 Principal investigator $356,062.23 46
PY2021 Principal investigator $527,634.01 76
PY2020 Principal investigator $306,669.77 74
PY2019 Principal investigator $67,433.90 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,352.50 12/18/2019 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689361
Principal investigator 1 PFIZER INC. $3,385.00 12/04/2019 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689357
Principal investigator 1 Genentech, Inc. $3,000.00 12/03/2019 Non-covered Recipient Entity
COMPLETE CHILDRENS HEALTH
PH III STUDY OF SAFETY EFFICACY OF CAP ENDONUCLEASE IN PEDIATRIC PATIENTS 1 12 YEARS No dispute reported 06/30/2026 681111723
Principal investigator 1 PFIZER INC. $5,940.00 11/23/2019 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689355
Principal investigator 1 Merck Sharp & Dohme Corporation $128.85 11/12/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691515483
Principal investigator 1 Merck Sharp & Dohme Corporation $80.55 11/12/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691516589
Principal investigator 1 Merck Sharp & Dohme Corporation $129.45 11/12/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691529637
Principal investigator 1 Merck Sharp & Dohme Corporation $141.70 11/12/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691529643
Principal investigator 1 PFIZER INC. $1,978.75 11/01/2019 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689307
Principal investigator 1 PFIZER INC. $15,405.00 10/22/2019 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689413
Principal investigator 1 SANOFI PASTEUR INC. $4,500.00 10/15/2019 Non-covered Recipient Entity
Midwest Childrens Health Research
MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine MCV4 No dispute reported 06/30/2026 691628113
Principal investigator 1 Genentech, Inc. $1,000.00 09/24/2019 Non-covered Recipient Entity
COMPLETE CHILDRENS HEALTH
PH III STUDY OF SAFETY EFFICACY OF CAP ENDONUCLEASE IN PEDIATRIC PATIENTS 1 12 YEARS No dispute reported 06/30/2026 681096369
Principal investigator 1 Merck Sharp & Dohme Corporation $110.57 09/21/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691439119
Principal investigator 1 Merck Sharp & Dohme Corporation $96.90 09/21/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691439425
Principal investigator 1 Merck Sharp & Dohme Corporation $223.20 09/11/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691519697
Principal investigator 1 PFIZER INC. $10,000.00 08/30/2019 Non-covered Recipient Entity
Midwest Childrens Health Research Institute
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689359
Principal investigator 1 Merck Sharp & Dohme Corporation $25.77 08/22/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691432919
Principal investigator 1 Merck Sharp & Dohme Corporation $28.34 08/22/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438351
Principal investigator 1 Merck Sharp & Dohme Corporation $16.11 08/22/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438831
Principal investigator 1 Merck Sharp & Dohme Corporation $25.89 08/22/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438981
Principal investigator 1 Merck Sharp & Dohme Corporation $773.99 08/22/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691452255
Principal investigator 1 Merck Sharp & Dohme Corporation $42.51 08/07/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691430809
Principal investigator 1 Merck Sharp & Dohme Corporation $129.45 07/24/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438009
Principal investigator 1 Merck Sharp & Dohme Corporation $80.55 07/24/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438479
Principal investigator 1 Merck Sharp & Dohme Corporation $128.85 07/24/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438493
Principal investigator 1 Merck Sharp & Dohme Corporation $99.19 07/24/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691440637
Principal investigator 1 Merck Sharp & Dohme Corporation $15.40 07/20/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438267
Principal investigator 1 Merck Sharp & Dohme Corporation $331.71 07/20/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438387
Principal investigator 1 Merck Sharp & Dohme Corporation $389.36 07/20/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438469
Principal investigator 1 Merck Sharp & Dohme Corporation $48.45 07/20/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691439709
Principal investigator 1 Merck Sharp & Dohme Corporation $30.80 06/21/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438357
Principal investigator 1 Merck Sharp & Dohme Corporation $331.71 06/21/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438383
Principal investigator 1 Merck Sharp & Dohme Corporation $778.72 06/21/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438473
Principal investigator 1 Merck Sharp & Dohme Corporation $48.45 06/21/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691439705
Principal investigator 1 Merck Sharp & Dohme Corporation $15.40 05/26/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691432545
Principal investigator 1 Merck Sharp & Dohme Corporation $389.36 05/26/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438465
Principal investigator 1 Merck Sharp & Dohme Corporation $64.60 05/26/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691438515
Principal investigator 1 Merck Sharp & Dohme Corporation $442.28 05/26/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691439029
Principal investigator 1 Merck Sharp & Dohme Corporation $7,150.80 03/21/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691318755
Principal investigator 1 Merck Sharp & Dohme Corporation $2,868.00 02/26/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691317155
Principal investigator 1 Merck Sharp & Dohme Corporation $1,105.70 02/20/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCHINSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691286907
Principal investigator 1 Merck Sharp & Dohme Corporation $141.28 02/20/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCHINSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691287987
Principal investigator 1 Merck Sharp & Dohme Corporation $1,557.44 02/20/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCHINSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691291489
Principal investigator 1 Merck Sharp & Dohme Corporation $184.10 02/20/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCHINSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691291501
Principal investigator 1 Merck Sharp & Dohme Corporation $389.36 02/03/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCHINSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691288766
Principal investigator 1 Merck Sharp & Dohme Corporation $55.23 02/03/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCHINSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691291123
Principal investigator 1 Merck Sharp & Dohme Corporation $331.71 02/03/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCHINSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691291703
Principal investigator 1 Merck Sharp & Dohme Corporation $35.32 02/03/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCHINSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691291709
Principal investigator 1 Merck Sharp & Dohme Corporation $1,905.60 01/10/2019 Non-covered Recipient Entity
MIDWEST CHILDRENS HEALTH RESEARCH INSTITUTE, LLC
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691309333